P4HB and breast carcinoma: Although the major results were consistent in showing that the inhibition of PDIA1 disrupted the cell cycle and diminished the transendothelial migration of breast cancer cells, the effects of pharmacological inhibition by bepristat 2a were more substantial compared with the silencing of PDIA1 in cancer cells.